Abcam, a prominent life science research tools provider, finalized its acquisition by Danaher Corporation at $24.00 per share in cash. The Court Order sanctioning the acquisition through a scheme of arrangement was issued, marking a step towards closing the deal. Trading of Abcam ADSs on Nasdaq is set to cease by December 6, 2023, following the Court Order’s delivery to the Registrar of Companies, as detailed in the Scheme Circular.
Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’) for $24.00 per share in cash (the ‘Transaction’), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).
Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.
Closing of the Transaction will occur and the Scheme will become effective upon the Court Order being delivered to the Registrar of Companies, which is expected to occur on December 6, 2023, as previously announced. The last day of trading in Abcam ADSs on Nasdaq is expected to be December 5, 2023, with trading in Abcam ADSs on Nasdaq being suspended by 8.00 a.m. (Eastern Time) on December 6, 2023.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Capitalized terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Scheme Circular.
Source: Bio Space